What used to be a mysterious new variant first detected in the UK is now the most dominant coronavirus strain in the US. And unlike the original strain of the novel coronavirus, the more contagious B.1.1.7 strain is hitting young people particularly hard.
Read MoreTens of thousands of people in the United States have lingering illness following COVID-19. In the US, we call them post-COVID "long haulers." Currently, the condition they are suffering from is known as "long COVID," although other names are being proposed.
Read MoreIn response to COVID-19 ongoing public health emergency, we developed an online interactive dashboard, hosted by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, Baltimore, MD, USA, to visualise and track reported cases of coronavirus disease 2019 (COVID-19) in real time.
Read MoreNumerous variants of SARS-CoV-2-harboring mutations in spike have arisen globally mRNA vaccines elicit potent neutralizing activity against homologous pseudovirus
Read MoreSARS-CoV-2 entry is mediated by the spike (S) glycoprotein which contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) as the two main targets of neutralizing antibodies (Abs). A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429) was originally detected in California and is currently
Read MoreLong COVID, or what doctors refer to as post-acute sequelae of COVID-19 (PASC), is a condition marked by the continuation of COVID-19 symptoms—or the emergence of new ones—after recovery from acute (or the initial phase of illness of) COVID-19.
Read MoreThe CDC is finalizing new guidelines for doctors on long-haul COVID-19.
Read MoreLong-haul COVID-19 patients face many health threats -- including a higher chance of dying -- up to 6 months after they catch the virus, according to a massive study published in the journal Nature.
Read MoreThere’s nothing new about fake news. For as long as there has been news, there has been misinformation, both deliberate and unintentional.
Read MoreIncreased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.
Read MoreClear Health Pass™ LLC acts as Authorized Representative of tribal, federally chartered corporations formed under Section 17 of the Indian Reorganization Act (IRA), U.S.C. Title 25.
(800) 266-7207
(212) 313-9529
© 2023 Clear Health Pass Holdings™, LLC., All trademark references are trademarks of either the Clear Health Pass Holdings, LLC or their respective owners.